- Open
- 9.50
- High
- 10.00
- Low
- 10.00
- Close
- 9.50
- Change
- -0.50 (-5.26%)
- Volume
- 1,600
| 10 Aug 2026 | 11:57:44 | Change of Registered Office |
| 3 Aug 2026 | 07:00:09 | First Patient Dosed with new Formulation of AO-252 |
| 7 Jul 2026 | 07:00:04 | Coiled Advances Next-Generation AO-252 Formulation |
| 24 Jun 2026 | 12:30:00 | Company Presentation |
| 25 Jun 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 20 May 2025 | 2024 Annual Report | |
| 1 May 2024 | 2023 ANNUAL REPORT AND FINANCIAL STATEMENTS |
Coiled Therapeutics PLC is a biotechnology company focused on developing AO-252, a small molecule inhibitor targeting the TACC3 protein, which is over-expressed in various cancer cells. The company holds an exclusive worldwide license for AO-252, which has demonstrated preclinical efficacy in treating ovarian, triple negative breast, endometrial, gastric, and prostate cancers, as well as brain metastases. Coiled Therapeutics is engaged in clinical trials for AO-252 in advanced solid tumors, aiming to address significant unmet medical needs in oncology.
| 10 Aug 2026 | 11:57:44 | Change of Registered Office |
| 3 Aug 2026 | 07:00:09 | First Patient Dosed with new Formulation of AO-252 |
| 7 Jul 2026 | 07:00:04 | Coiled Advances Next-Generation AO-252 Formulation |
| 24 Jun 2026 | 12:30:00 | Company Presentation |
| 25 Jun 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 20 May 2025 | 2024 Annual Report | |
| 1 May 2024 | 2023 ANNUAL REPORT AND FINANCIAL STATEMENTS |
Coiled Therapeutics PLC is a biotechnology company focused on developing AO-252, a small molecule inhibitor targeting the TACC3 protein, which is over-expressed in various cancer cells. The company holds an exclusive worldwide license for AO-252, which has demonstrated preclinical efficacy in treating ovarian, triple negative breast, endometrial, gastric, and prostate cancers, as well as brain metastases. Coiled Therapeutics is engaged in clinical trials for AO-252 in advanced solid tumors, aiming to address significant unmet medical needs in oncology.
| 24 Jun 2026 | 11:18:46 | Result of AGM |
| 24 Jun 2026 | 11:18:46 | Result of AGM |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £1.55bn | -0.2% | |
| £315m | +0.4% | |
COILCoiled Therapeutics PLC | £41m | — |
| £21m | +1.2% | |
| £12m | +0.3% | |
| £4m | +1.1% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £1.55bn | -0.2% | |
| £315m | +0.4% | |
COILCoiled Therapeutics PLC | £41m | — |
| £21m | +1.2% | |
| £12m | +0.3% | |
| £4m | +1.1% |
